Indian drugmakers giving up ‘advantage’ to move to higher-margin drugs – FiercePharma Manufacturing
0
The “Indian advantage” has been the ability to do clinical trials and manufacture drugs for global export at perhaps a tenth of the cost that drugmakers in the West face. But with actions by the FDA and Western regulators forcing plants from exporting to those markets and a need to move to higher-margin drugs, some Indian drugmakers are giving up that edge in an effort to raise profits.
“We have lost what is called the India advantage,” Swati Piramal, vice-chair of Mumbai-based Piramal Enterprises, told Reuters. But she said “the new alternative” is to acquire small groups of people who have the expertise to research and make a particular type of product…
Read more – FiercePharma Manufacturing